BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 4, 2002
View Archived Issues
ImClone Submits Two Phase III Protocols For Erbitux To FDA
Read More
Amgen Among First Impacted By New Reimbursement Plan
It appears that Amgen Inc. could fall victim to a government reimbursement program that calls its anemia drug Aranesp "functionally equivalent" to a similar product, Procrit, made by Johnson & Johnson. (BioWorld Today)
Read More
Ants, Winged And Wingless, Duel To The Death For Wafted Chemical Favors From Queens
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More